drugset / Trial / NCT01397149
Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)
Phase 1/2
Terminated
4 enrolled
University of Ulm
German CLL Study Group · collabGlaxoSmithKline · collabWiSP Wissenschaftlicher Service Pharma GmbH · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim of this study is to find the appropriate dose of eltrombopag in thrombocytopenic CLL patients, that shortens the duration of the thrombocytopenia and achieves platelet count of ≥ 100/nl prior to the start of chemotherapy containing alkylating agents and/or Purine Analogues.
Timeline
- Start
- 2011-10
- Primary completion
- 2013-11
- Completion
- 2014-11
Outcome
Outcome not reported
Stopped (Enrollment): “Insufficient recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eltrombopag | Small molecule | 75 mg | — |
| Subject | Eltrombopag | Small molecule | 150 mg | — |
| Subject | Eltrombopag | Small molecule | 225 mg | — |
| Subject | Eltrombopag | Small molecule | 300 mg | — |